Summary
Despite the generalization of induction chemotherapy and a better outcome for chemosensitive diseases, the prognosis of inflammatory breast cancer (IBC) is still poor. In this work, we evaluate response and toxicity of high-dose sequential chemotherapy with repeated blood stem cell (BSC) transplantation administered as initial treatment in 100 women with non-metastatic IBC. Ninety-five patients (five patients were evaluated as non-eligible) of median age 46 years (range 26–56) received four cycles of chemotherapy associating: cyclophosphamide (C) 6 g m−2 – doxorubicin (D) 75 mg m−2 cycle 1, C: 3 g m−2 – D: 75 mg m−2 cycle 2, C: 3 g m−2 – D: 75 mg m−2 – 5 FU 2500 mg m−2 cycle 3 and 4. BSC were collected after cycle 1 or 2 and reinfused after cycle 3 and 4. rG-CSF was administered after the four cycles. Mastectomy and radiotherapy were planned after chemotherapy completion. Pathological response was considered as the first end point of this trial. A total of 366 cycles of chemotherapy were administered. Eighty-seven patients completed the four cycles and relative dose intensity was respectively 0.97 (range 0.4–1.04) and 0.96 (range 0.25–1.05) for C and D. Main toxicity was haematological with febrile neutropenia ranging from 26% to 51% of cycles; one death occurred during aplasia. Clinical response rate was 90% ± 6%. Eighty-six patients underwent mastectomy in a median of 3.5 months (range 3–9) after the first cycle of chemotherapy; pathological complete response rate in breast was 32% ± 10%. All patients were eligible to receive additional radiotherapy. High-dose chemotherapy with repeated BSC transplantation is feasible with acceptable toxicity in IBC. Pathological response rate is encouraging but has to be confirmed by final outcome.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Antman, K, Gale, RP (1988). Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 108: 570–574.
Armstrong, DK, Fetting, JH, Davidson, NE, Gordon, GB, Huelskamp, AM & Abeloff, MD (1993). Sixteen-week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat 28: 277–284.
Basser, RL, To, LB, Begley, CG, Juttner, CA, Maher, DW, Szer, J, Cebon, J, Russel, I, Olver, I, Gill, PG, Fox, RM, Sheridan, WP & Green, MD (1995). Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Clin Cancer Res 1: 715–721.
Bauer, RL, Busch, E, Levine, E & Edge, SB (1995). Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol 2: 288–294.
Bezwoda, WR, Seymour, L & Dansey, RD (1995). High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13: 2483–2489.
Brugger, W, Bross, KJ, Glatt, M, Weber, F, Mertelsmann, R & Kanz, L (1994). Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83: 636–640.
Chevallier, B, Asselain, B, Kunlin, A, Veyret, C, Bastit, P & Graic, Y (1987). Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer 60: 897–902.
Chevallier, B, Chollet, P, Merrouche, Y, Roche, H, Fumoleau, P, Kerbrat, P, Genot, JY, Fargeot, JP, Olivier, JP, Fizames, C, Clavel, M, Yver, M & Cour Chabernaud, V (1995). Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13: 1564–1571.
Colozza, M, Gori, S, Mosconi, AM, Anastasi, P, De Angelis, V, Giansanti, M, Mercati, U, Aristei, C, Latini, P & Tonato, M (1996). Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. Am J Clin Oncol 19: 10–17.
Feldman, LD, Hortobagyi, GN, Buzdar, AU, Ames, FC & Blumenschein, GR (1986). Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578–2581.
Fisher, B, Anderson, S, Wickerham, DL, DeCillis, A, Dimitrov, N, Mamounas, E, Wolmark, N, Pugh, R, Atkins, JN, Meyers, FJ, Abramson, N, Wolter, J, Bornstein, RS, Levy, L, Romond, EH, Caggiano, V, Grimaldi, M, Jochimsem, P & Deckers, P (1997). Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from national surgical adjuvant breast and bowel project B-22. J Clin Oncol 15: 1858–1869.
Fleming, TR (1982). One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143–151.
Frei, EIII, Canellos, GP (1980). Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585–594.
Gianni, AM, Siena, S, Bregni, M, Di Nicola, M, Orefice, S, Cusumano, F, Salvadori, B, Luini, A, Greco, M, Zucali, R, Rilke, F, Zambetti, M, Valagussa, P & Bonadonna, G (1997). Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 15: 2312–2321.
Griswold, DP Jr, Trader, MW, Frei, EI, Peters, WP, Wolpert, MK & Laster, WR Jr (1987). Response of drug-sensitive and resistant L1210 leukemias to high-dose chemotherapy. Cancer Res 47: 2323–2327.
Hryniuk, W & Bush, H (1984). The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1288.
Israel, L, Breau, J & Morere, J (1986). Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. Cancer 57: 24–28.
Jaiyesimi, IA, Buzdar, AU & Hortobagyi, GN (1992). Inflammatory breast cancer: a review. J Clin Oncol 10: 1014–1024.
Kaplan, EL & Meier, P (1971). Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Maloisel, F, Dufour, P, Bergerat, JP, Herbrecht, R, Duclos, B, Boilletot, A, Giron, C, Jaeck, D, Haennel, P, Jung, G & Oberling, F (1990). Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 65: 851–855.
Nieto, Y, Cagnoni, PJ, Bearman, SI, Shpall, EJ, Ross, M & Jones, RB (1997). High-dose chemotherapy (HDC) with cisplatin (CDDP), cyclophosphamide (CPA) and BCNU (CCB), followed by autologous hematopoietic progenitor cell support (AHPCS) for inflammatory breast cancer (IBC). In Proceedings of Asco Vol. 16. pp. 436: Denver, CO.
Noguchi, S, Miyauchi, K, Nishizawa, Y, Koyama, H & Terasawa, T (1988). Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Cancer 61: 1483–1491.
Palangie, T, Mosseri, V, Mihura, J, Campana, F, Beuzeboc, P, Dorval, T, Garcia-Giralt, E, Jouve, M, Scholl, S, Asselain, B & Pouillart, P (1994). Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A: 921–927.
Peters, WP, Ross, M, Vredenburgh, JJ, Meisenberg, B, Marks, LB, Winer, E, Kurtzberg, J, Bast, RC Jr, Jones, R, Shpall, E, Wu, K, Rosner, G, Gilbert, C, Mathias, B, Coniglio, D, Petros, W, Henderson, IC, Norton, L, Weiss, RB, Budman, DR & Hurd, D (1993). High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132–1143.
Rosti, G, Vertogen, B, Ferrante, P, Turazza, M, Lelli, G, Sabbatini, R, Frassineti, GL, Tienghi, A & Marangolo, M (1997). High-dose mitoxantrone, thiotepa and cyclophosphamide with peripheral blood progenitor cells (PBPC) support for inflammatory breast carcinoma; an Italian study In: Proceedings of Asco, Vol. 16: pp. 125: Denver, CO
Rouëssé, J, Friedman, S, Sarrazin, D, Mouriesse, H, Le Chevalier, T, Arriagada, R, Spielmann, M, Papacharalambous, A & May-Levin, F (1986). Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave Roussy. J Clin Oncol 4: 1765–1771.
Sataloff, DM, Mason, BA, Prestipino, AJ, Seinige, UL, Lieber, CP & Baloch, Z (1995). Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297–304.
Shipp, MA, Neuberg, D, Janicek, M, Canellos, GP & Shulman, LN (1995). High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin’s lymphoma: a dose-finding pilot study. J Clin Oncol 13: 2916–2923.
Stoppa, AM, Bouabdallah, R, Chabannon, C, Novakovitch, G, Vey, N, Camerlo, J, Blaise, D, Xerri, L, Resbeut, M, Di Stefano, D, Bardou, VJ, Gastaut, JA & Maraninchi, D (1997). Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin’s lymphoma. J Clin Oncol 15: 1722–1729.
Swain, SM & Lippman, ME (1989). Treatment of patients with inflammatory breast cancer. In: Important Advances in Oncology, De Vita VT Jr, Rosenberg SA (ed), pp. 129–150. Lippincott: Philadelphia, PA
Swain, SM, Rowland, J, Weinfurt, K, Berg, C, Lippman, ME, Walton, L, Egan, E, King, D, Spertus, I & Honig, SF (1996). Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. J Clin Oncol 14: 1565–1572.
Viens, P, Gravis, G, Genre, D, Bertucci, F, Cowen, D, Camerlo, J, Cappiello, MA, Conte, M, Finaud, M, Chabannon, C, Houvenaeghel, G & Maraninchi, D (1997). High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer. Bone Marrow Transplant 20: 199–203.
Viens, P, Penault-Llorca, F, Jacquemier, J, Gravis, G, Cowen, D, Bertucci, F, Houvenaeghel, G, Blaise, D & Maraninchi, D (1998). High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 21: 249–254.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Viens, P., Palangié, T., Janvier, M. et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 81, 449–456 (1999). https://doi.org/10.1038/sj.bjc.6690714
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690714
Keywords
This article is cited by
-
Overview of preoperative radiochemotherapy in breast cancer: past or future?
Clinical and Translational Oncology (2011)
-
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)
Clinical and Translational Oncology (2011)